Efficacy comparison of dapagliflozin combined with liraglutide versus monotherapy in obese patients with heart failure.

Medicine (Baltimore) · 2026 · PMC13034935 · PMID 41894290

Europe PMC DOI

hedged sentence

0.1250

closest p · 2.5× alpha

0.1250

boldest claim

The sentences

did not reach statistical significanceP = .125not close (p > 0.1)

Regarding specific major cardiovascular events, the incidence was 10.0% (12 patients) in the combination group, numerically lower than 18.3% (22 patients) in the dapagliflozin group and 16.7% (20 patients) in the liraglutide group; although this difference did not reach statistical significance ( P = .125), it suggests a potential benefit of combination therapy in reducing cardiovascular events.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.